Vericel Corp
Vericel is dedicated to developing and manufacturing innovative cell therapies and specialty biologics for the sports medicine and severe burn care markets. The company aims to improve the lives of patients with serious conditions through advanced therapies, including products like MACI, Epicel, and NexoBrid, and is committed to innovation, patient safety, and ethical business practices.
Industries
Nr. of Employees
large (251-1000)
Vericel Corp
Patents
Mixed cell populations for tissue repair and separation technique for cell processing
US-9415071-B2
View DetailsMixed cell populations for tissue repair and separation technique for cell processing
US-8394631-B2
View Details
Mixed cell populations for tissue repair and separation technique for cell processing
US-9415071-B2
View DetailsMixed cell populations for tissue repair and separation technique for cell processing
US-8394631-B2
View DetailsProducts
MACI (autologous cultured chondrocytes on collagen membrane)
Autologous cellularized scaffold product produced by culturing a patient’s chondrocytes on a collagen membrane intended to repair symptomatic, full-thickness cartilage defects of the knee.
Epicel (cultured epidermal autografts)
Cultured epidermal autografts produced from a patient’s own skin biopsy to provide permanent skin replacement for deep dermal or full-thickness burns covering large total body surface areas.
NexoBrid (topical proteolytic enzymatic debridement)
Topical botanical proteolytic enzyme formulation indicated for selective eschar removal in adults and pediatric patients with deep partial- and/or full-thickness thermal burns.
MACI (autologous cultured chondrocytes on collagen membrane)
Autologous cellularized scaffold product produced by culturing a patient’s chondrocytes on a collagen membrane intended to repair symptomatic, full-thickness cartilage defects of the knee.
Epicel (cultured epidermal autografts)
Cultured epidermal autografts produced from a patient’s own skin biopsy to provide permanent skin replacement for deep dermal or full-thickness burns covering large total body surface areas.
NexoBrid (topical proteolytic enzymatic debridement)
Topical botanical proteolytic enzyme formulation indicated for selective eschar removal in adults and pediatric patients with deep partial- and/or full-thickness thermal burns.
Services
Competitive evaluation and potential financial or in-kind support for investigator-led clinical studies, educational activities, and qualified charitable initiatives via formal application processes.
Documented policy and medical affairs contact process to consider requests for access to investigational therapies outside clinical trials consistent with FDA guidance.
Channels and procedures for reporting adverse events, medical device reports, other safety findings, and product complaints including hotlines, email reporting, and product event intake forms.
Competitive evaluation and potential financial or in-kind support for investigator-led clinical studies, educational activities, and qualified charitable initiatives via formal application processes.
Documented policy and medical affairs contact process to consider requests for access to investigational therapies outside clinical trials consistent with FDA guidance.
Channels and procedures for reporting adverse events, medical device reports, other safety findings, and product complaints including hotlines, email reporting, and product event intake forms.
Expertise Areas
- Cell therapy development and commercialization
- Orthopedic cartilage repair and joint preservation
- Severe burn care and cultured skin grafts
- Clinical trial management for multicenter randomized studies
Key Technologies
- Tissue-engineered cell-seeded scaffolds
- Autologous cell expansion and culture
- Cultured epidermal autograft production
- Topical proteolytic enzymatic debridement (bromelain-based)
News & Updates
Vericel announced that the first patient was treated arthroscopically using MACI Arthro™ instrumentation, marking a milestone in providing innovative solutions for cartilage defects.
The FDA approved MACI for repairing cartilage defects in the knee, using a patient’s own cells cultured on a collagen membrane, delivered arthroscopically.
Vericel expanded its MACI label to include arthroscopic delivery for knee cartilage repair.
The FDA approved a pediatric indication for NexoBrid for eschar removal in deep partial- and full-thickness thermal burns.
The FDA expanded the approval of NexoBrid to include eschar removal in pediatric patients aged 0-18 with deep partial- and full-thickness burns.
Vericel is positioned to capitalize on the rapid growth of the cell therapy market, which is expected to grow significantly in the coming years.
Vericel announced that the first patient was treated arthroscopically using MACI Arthro™ instrumentation, marking a milestone in providing innovative solutions for cartilage defects.
The FDA approved MACI for repairing cartilage defects in the knee, using a patient’s own cells cultured on a collagen membrane, delivered arthroscopically.
Vericel expanded its MACI label to include arthroscopic delivery for knee cartilage repair.
The FDA approved a pediatric indication for NexoBrid for eschar removal in deep partial- and full-thickness thermal burns.
The FDA expanded the approval of NexoBrid to include eschar removal in pediatric patients aged 0-18 with deep partial- and full-thickness burns.
Vericel is positioned to capitalize on the rapid growth of the cell therapy market, which is expected to grow significantly in the coming years.